Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients Genentech, 15 Oct 2010 Accessed on 7 Dec 2011 from http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12987. CommentRecommendBookmarkWatch